Treatment of shock using adrenomedullin binding protein-1

Details Treatment of shock using adrenomedullin binding protein-1 Treatment of shock using adrenomedullin binding protein-1

2005-04-26

2005-04-26

Wax, Robert A. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S094100, C435S183000

Reexamination Certificate

active

06884781

ABSTRACT:
Methods of treating a mammal in shock or at risk for shock are provided. The methods involve administration of an adrenomedullin binding protein-1 to the mammal. Also provided are methods of preventing or treating a physiologic effect of shock in a mammal. These methods also involve administration of an adrenomedullin binding protein-1 to the mammal.

REFERENCES:
Yang et al., Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: Down regulation of proinflammatory cytokines, 2002, Critical Care Medicine, 30(12), 2729-35.*
Elsasser T.H. et al., “Adrenomedullin binding protein in the plasma of multiple species: characterization by radioligand blotting”; Endocrinol 140:4908-4911, 1999.
Shindo T. et al., “Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature”; Circulation 101:2309-2316, 2000.
Wichterman K.A. et al., “Sepsis and septic shock: a review of laboratory models and a proposal”; J Surg Res 29:189-201, 1980.
Wu R. et al., “Adrenomedullin and adrenomedullin binding protein-1 downregulate TNF-alpha in macrophage cell line and rat Kupffer cells”; Regul Pept 112:19-26, 2003.
Yang S et al., “Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: The role of adrenomedullin and adrenomedullin binding protein-1”; Crit Care Med. 29 (12, Suppl.); abst. A12, Dec. 2001.
Yang S. et al., “Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: Role of adrenomedullin and adrendomedullin binding protein-1”; Ann Surg 236:625-633, 2002.
Yang S. et al., “Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines”; Crit Care Med 30:2729-2735, 2002.

Affiliated with

Also associated with

Rating

Treatment of shock using adrenomedullin binding protein-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of shock using adrenomedullin binding protein-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of shock using adrenomedullin binding protein-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3381700